Friday, May 22, 2026
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Cardiff To Present Data At ASCO. Cardiff Oncology reported a 1Q26 loss of $12.4 million or $(0.18) per share. Important developments during the quarter include scheduling presentation of the Phase 2b trial, discussed in our Research Note on January 28, at the ASCO Annual Meeting from May 29 to June 2. A meeting with the FDA was held in April, with the Phase 3 trial still expected to begin in late FY2026. Cash on March 31, 2026, was $46.1 million.
End-of-Phase-2 Meeting With The FDA Completed. During 1Q26, the company held an End-of-Phase-2 Meeting with the FDA to obtain guidance on the Phase 3 design and regulatory approval requirements. As expected, the trial will enroll patients with RAS-mutated metastatic colorectal cancer (mCRC), treated with a combination of FOLFIRI with bevacizumab (Avastin) and the 30 mg dose of onvansertib. This is the regimen that produced the strongest results in the Phase 2b trial.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
